| P2093 | author name string | Kevin M Flanigan | |
| | Paul T Martin | |
| | Guohong Shao | |
| | Kelly E Crowe | |
| P2860 | cites work | Processing and secretion of the N-terminal domain of alpha-dystroglycan in cell culture media | Q24306720 |
| | Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy | Q24310537 |
| | Expression profiling of cytokines and related genes in regenerating skeletal muscle after cardiotoxin injection: a role for osteopontin | Q24685614 |
| | Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix | Q28296676 |
| | A Method to Produce and Purify Full-Length Recombinant Alpha Dystroglycan: Analysis of N- and O-Linked Monosaccharide Composition in CHO Cells with or without LARGE Overexpression | Q28485391 |
| | Association of dystrophin-related protein with dystrophin-associated proteins in mdx mouse muscle | Q28510608 |
| | 204th ENMC International Workshop on Biomarkers in Duchenne Muscular Dystrophy 24-26 January 2014, Naarden, The Netherlands | Q28611318 |
| | Membrane organization of the dystrophin-glycoprotein complex | Q29615149 |
| | Dystrophin: the protein product of the Duchenne muscular dystrophy locus | Q29618077 |
| | Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals | Q30050310 |
| | Dystrophin as a therapeutic biomarker: are we ignoring data from the past? | Q30809362 |
| | Sporadic inclusion body myositis: a continuing puzzle | Q33345016 |
| | Creatine kinase, cell membrane and Duchenne muscular dystrophy | Q33547058 |
| | Systemic administration of PRO051 in Duchenne's muscular dystrophy | Q34172661 |
| | A Human-Specific Deletion in Mouse Cmah Increases Disease Severity in the mdx Model of Duchenne Muscular Dystrophy | Q34175938 |
| | Three novel serum biomarkers, miR-1, miR-133a, and miR-206 for Limb-girdle muscular dystrophy, Facioscapulohumeral muscular dystrophy, and Becker muscular dystrophy | Q34534211 |
| | Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients | Q34555477 |
| | Dystromirs as serum biomarkers for monitoring the disease severity in Duchenne muscular Dystrophy | Q35055089 |
| | Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy | Q35069526 |
| | Dystroglycan glycosylation and its role in matrix binding in skeletal muscle | Q35123507 |
| | Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy | Q35740280 |
| | Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy | Q35750055 |
| | Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort | Q36116293 |
| | A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. | Q36232550 |
| | Creatine kinase: a review of its use in the diagnosis of muscle disease. | Q36346293 |
| | New approaches in the therapy of cardiomyopathy in muscular dystrophy | Q36705183 |
| | The synaptic CT carbohydrate modulates binding and expression of extracellular matrix proteins in skeletal muscle: Partial dependence on utrophin | Q37361308 |
| | Functional diversity of dystroglycan | Q37419780 |
| | The three-dimensional structure of a glutathione S-transferase from the mu gene class. Structural analysis of the binary complex of isoenzyme 3-3 and glutathione at 2.2-A resolution | Q38325077 |
| | Genetics and emerging treatments for Duchenne and Becker muscular dystrophy. | Q38506553 |
| | A High-Throughput Assay for the Detection of α-Dystroglycan N-Terminus in Human Uterine Fluid to Determine Uterine Receptivity | Q38814287 |
| | Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD). | Q39732882 |
| | Plectin 1f scaffolding at the sarcolemma of dystrophic (mdx) muscle fibers through multiple interactions with beta-dystroglycan. | Q39734956 |
| | Embryonic overexpression of Galgt2 inhibits skeletal muscle growth via activation of myostatin signaling | Q39904673 |
| | Proteolytic enzymes and altered glycosylation modulate dystroglycan function in carcinoma cells. | Q40519860 |
| | Non-Invasive Biomarkers for Duchenne Muscular Dystrophy and Carrier Detection | Q40820281 |
| | Contractile properties of skeletal muscles from young, adult and aged mice | Q41421042 |
| | Increased activity of calcium leak channels in myotubes of Duchenne human and mdx mouse origin | Q44177784 |
| | Eteplirsen for the treatment of Duchenne muscular dystrophy | Q45855674 |
| | Increased protein degradation results from elevated free calcium levels found in muscle from mdx mice | Q46266620 |
| | Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice. | Q52187735 |
| | Plectin defects in epidermolysis bullosa simplex with muscular dystrophy. | Q52573505 |
| | Proteomics profiling of urine reveals specific titin fragments as biomarkers of Duchenne muscular dystrophy. | Q54353800 |
| | Fibronectin is a serum biomarker for Duchenne muscular dystrophy | Q57389875 |
| | Crystallization of glutathione S-transferase from human placenta | Q57838300 |
| | The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy | Q59051261 |
| | Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene | Q59053234 |
| | Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle | Q59089242 |
| | Dystrophin-related protein is localized to neuromuscular junctions of adult skeletal muscle | Q68255626 |
| | The molecular basis of muscular dystrophy in the mdx mouse: a point mutation | Q69514522 |
| | Use of serum creatine kinase, pyruvate kinase, and genetic linkage for carrier detection in Duchenne and Becker dystrophy | Q69892059 |
| | Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy | Q73677664 |
| | Local dystrophin restoration with antisense oligonucleotide PRO051 | Q80412961 |
| | Evidence-based path to newborn screening for Duchenne muscular dystrophy | Q83749785 |
| | Secretion of N-terminal domain of α-dystroglycan in cerebrospinal fluid | Q84528305 |
| | The N-terminal domain of α-dystroglycan, released as a 38 kDa protein, is increased in cerebrospinal fluid in patients with Lyme neuroborreliosis | Q84769257 |
| P433 | issue | 2 | |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 247-260 | |
| P577 | publication date | 2016-05-01 | |
| P1433 | published in | Journal of neuromuscular diseases | Q27726242 |
| P1476 | title | N-terminal α Dystroglycan (αDG-N): A Potential Serum Biomarker for Duchenne Muscular Dystrophy | |
| P478 | volume | 3 | |